» Articles » PMID: 28301858

Anti-nerve Growth Factor Therapy Increases Spontaneous Day/night Activity in Mice with Orthopedic Surgery-induced Pain

Overview
Journal Pain
Specialties Neurology
Psychiatry
Date 2017 Mar 17
PMID 28301858
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Total knee arthroplasty (TKA) and total hip arthroplasty (THA) are 2 of the most common and successful surgical interventions to relieve osteoarthritis pain. Control of postoperative pain is critical for patients to fully participate in the required physical therapy which is the most influential factor in effective postoperative knee rehabilitation. Currently, opiates are a mainstay for managing postoperative orthopedic surgery pain including TKA or THA pain. Recently, issues including efficacy, dependence, overdose, and death from opiates have made clinicians and researchers more critical of use of opioids for treating nonmalignant skeletal pain. In the present report, a nonopiate therapy using a monoclonal antibody raised against nerve growth factor (anti-NGF) was assessed for its ability to increase the spontaneous activity of the operated knee joint in a mouse model of orthopedic surgery pain-induced by drilling and coring the trochlear groove of the mouse femur. Horizontal activity and velocity and vertical rearing were continually assessed over a 20 hours day/night period using automated activity boxes in an effort to reduce observer bias and capture night activity when the mice are most active. At days 1 and 3, after orthopedic surgery, there was a marked reduction in spontaneous activity and vertical rearing; anti-NGF significantly attenuated this decline. The present data suggest that anti-NGF improves limb use in a rodent model of joint/orthopedic surgery and as such anti-NGF may be useful in controlling pain after orthopedic surgeries such as TKA or THA.

Citing Articles

Targeting nerve growth factor for pain relief: pros and cons.

Jaffal S, Khalil R Korean J Pain. 2024; 37(4):288-298.

PMID: 39322310 PMC: 11450303. DOI: 10.3344/kjp.24235.


Pathology of pain and its implications for therapeutic interventions.

Cao B, Xu Q, Shi Y, Zhao R, Li H, Zheng J Signal Transduct Target Ther. 2024; 9(1):155.

PMID: 38851750 PMC: 11162504. DOI: 10.1038/s41392-024-01845-w.


Acute postoperative pain and dorsal root ganglia transcriptomic signatures following total knee arthroplasty (TKA) in rats: An experimental study.

Komatsu D, Uddin S, Gordon C, Kanjiya M, Bogdan D, Achonu J PLoS One. 2022; 17(12):e0278632.

PMID: 36473007 PMC: 9725137. DOI: 10.1371/journal.pone.0278632.


A Novel Rat Model to Study Postsurgical Pain After Joint Replacement Surgery.

Aoyama N, Izumi M, Morimoto T, Wada H, Dan J, Kasai Y J Pain Res. 2022; 15:2911-2918.

PMID: 36132997 PMC: 9482957. DOI: 10.2147/JPR.S368130.


Monoclonal Antibodies for Chronic Pain Treatment: Present and Future.

Sanchez-Robles E, Giron R, Paniagua N, Rodriguez-Rivera C, Pascual D, Goicoechea C Int J Mol Sci. 2021; 22(19).

PMID: 34638667 PMC: 8508878. DOI: 10.3390/ijms221910325.


References
1.
Wang M, Shen J, Jin H, Im H, Sandy J, Chen D . Recent progress in understanding molecular mechanisms of cartilage degeneration during osteoarthritis. Ann N Y Acad Sci. 2011; 1240:61-9. PMC: 3671949. DOI: 10.1111/j.1749-6632.2011.06258.x. View

2.
Hochberg M . Serious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodies. Osteoarthritis Cartilage. 2014; 23 Suppl 1:S18-21. DOI: 10.1016/j.joca.2014.10.005. View

3.
Ryu J, Saito S, Yamamoto K, Sano S . Factors influencing the postoperative range of motion in total knee arthroplasty. Bull Hosp Jt Dis. 1993; 53(3):35-40. View

4.
Stubbs B, Binnekade T, Soundy A, Schofield P, Huijnen I, Eggermont L . Are older adults with chronic musculoskeletal pain less active than older adults without pain? A systematic review and meta-analysis. Pain Med. 2013; 14(9):1316-31. DOI: 10.1111/pme.12154. View

5.
Wernham B, Trumpatori B, Hash J, Lipsett J, Davidson G, Wackerow P . Dose reduction of meloxicam in dogs with osteoarthritis-associated pain and impaired mobility. J Vet Intern Med. 2011; 25(6):1298-305. DOI: 10.1111/j.1939-1676.2011.00825.x. View